AOD9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
By August, eight of the nine republics, except Ukraine, had approved the draft of the new Treaty with some conditions. Ukraine did not agree on the terms of the Treaty. In the simultaneous Ukrainian republican referendum on 17 March, the majority of residents of Ukraine supported joining the Union on the basis of the 16 July 1990 Declaration of State Sovereignty of Ukraine. In addition, most of autonomous republics expressed the desire to raise their status and to be a party to the new Soviet treaty and declared sovereignty and self-promotion to republics during the parade of sovereignties in the months following the initial proposal from July 1990. Most of them participated in the Novo-Ogaryovo process to draft the treaty, and the status of former autonomous republics was a major point of contention among participants. On July 12, 1991, the Supreme Soviet passed the resolution "About the draft treaty on Union of Sovereign States" to state its stance on the matter that each of "the subjects of the federation, including both the sovereign states - the republics - and the republics incorporated within them on a treaty or constitutional basis" "possesses the right to sign the text of the Union Treaty". As a compromise, the final draft of the treaty allowed a state to join the Union as a part of another state, but only the nine republics were invited to sign it at Novo-Ogaryovo on July 23. Following the August coup, the New Union Treaty was further reformed into the Commonwealth of Independent States.
The separation is the inverse of the maximum OPD. For example, a maximum OPD of 2 cm results in a separation of 0.5 cm−1. This is the spectral resolution in the sense that the value at one point is independent of the values at adjacent points. Most instruments can be operated at different resolutions by choosing different OPD's. Instruments for routine analyses typically have a best resolution of around 0.5 cm−1, while spectrometers have been built with resolutions as high as 0.001 cm−1, corresponding to a maximum OPD of 10 m. The point in the interferogram corresponding to zero path difference has to be identified, commonly by assuming it is where the maximum signal occurs. This so-called centerburst is not always symmetrical in real world spectrometers so a phase correction may have to be calculated. The interferogram signal decays as the path difference increases, the rate of decay being inversely related to the width of features in the spectrum. If the OPD is not large enough to allow the interferogram signal to decay to a negligible level there will be unwanted oscillations or sidelobes associated with the features in the resulting spectrum. To reduce these sidelobes the interferogram is usually multiplied by a function that approaches zero at the maximum OPD. This so-called apodization reduces the amplitude of any sidelobes and also the noise level at the expense of some reduction in resolution. For rapid calculation the number of points in the interferogram has to equal a power of two. A string of zeroes may be added to the measured interferogram to achieve this.
A milkette (also referred to as dairy milker, creamette or creamers) is a single serving of milk (2%) or cream (10% and 18%) in 12 millilitres (0.42 imp fl oz; 0.41 US fl oz) or 15 millilitres (0.53 imp fl oz; 0.51 US fl oz) containers used for coffee and tea. The single cup of milk is stored in a sealed (foil cover) plastic cup of milk or cream with long shelf life but must be refrigerated.
== History == The study of extracellular metabolites has been prevalent in scientific literature. However, global exometabolite profiling was only realized with recent advances allowing for improved chromatographic separation and detection of hundreds to thousands of compounds by the mid-2000s. The first work to demonstrate the biological relevance of comparative profiling of exometabolite pools was not until 2003, when the term "metabolite footprinting" was coined by Jess Allen and coworkers. This work attracted a great deal of interest in the community, particularly for characterization of microbial metabolism. The idea of the "exometabolome" encompassing the components of the exometabolite pool was not introduced until 2005. Recent advances in mass spectrometry imaging have allowed for spatial localization of released metabolites. As the field of microbiology becomes increasingly more centered on microbial community structure, exometabolomics has provided for rapid understanding of metabolic interactions between two or more species. Recently, exometabolomics has been used to design co-culture systems. Because the analysis of extracellular metabolites allows for the predictions and determinations of metabolite exchange, exometabolomics analyses can be used for understanding community ecological networks.
In the early 1960s, Dayhoff also collaborated with Ellis Lippincott and Carl Sagan to develop thermodynamic models of cosmo-chemical systems, including prebiological planetary atmospheres. She developed a computer program that could calculate equilibrium concentrations of the gases in a planetary atmosphere, enabling the study of the atmospheres of Venus, Jupiter, and Mars, in addition to the present day atmosphere and the primordial terrestrial atmosphere. Using this program, she considered whether the primordial atmosphere had the conditions necessary to generate life. Although she found that numerous small biologically important compounds can appear with no special nonequilibrium mechanism to explain their presence, there were compounds necessary to life that were scarce in the equilibrium model (such as ribose, adenine, and cytosine). Dayhoff also taught physiology and biophysics at Georgetown University Medical Center for 13 years, served as a Fellow of the American Association for the Advancement of Science and was elected councillor of the International Society for the Study of the Origins of Life in 1980 after 8 years of membership. Dayhoff also served on the editorial boards of three journals: DNA, Journal of Molecular Evolution and Computers in Biology and Medicine.
Sources: en.wikipedia.org
=== In plants and animals === Capillary action is seen in many plants, and plays a part in transpiration. Water is brought high up in trees by branching; evaporation at the leaves creating depressurization; probably by osmotic pressure added at the roots; and possibly at other locations inside the plant, especially when gathering humidity with air roots. Capillary action for uptake of water has been described in some small animals, such as Ligia exotica and Moloch horridus.
Anapsida – no fenestrae – cotylosaurs and chelonia (turtles and relatives) Synapsida – one low fenestra – pelycosaurs and therapsids (the 'mammal-like reptiles') Euryapsida – one high fenestra (above the postorbital and squamosal) – protorosaurs (small, early lizard-like reptiles) and the marine sauropterygians and ichthyosaurs, the latter called Parapsida in Osborn's work. Diapsida – two fenestrae – most reptiles, including lizards, snakes, crocodilians, dinosaurs and pterosaurs.
In 1918, he was awarded the license to practise medicine, surgery, and midwifery by the Royal College of Physicians of London. He studied orthopedic medicine and, in 1919–1920, was Resident Surgeon at The Hospital for Sick Children. Because he was unable to gain a place on the hospital staff, he decided to move to London, Ontario, to set up a medical practice. After his medical practice proved unsuccessful, Banting returned to general practice from July 1920 to May 1921 and began teaching orthopedics and anthropology part-time at the University of Western Ontario in London, Ontario. From 1921 to 1922 he lectured in pharmacology at the University of Toronto. He received his M.D. degree in 1922, and was also awarded a gold medal.
=== Environmental impact === Refinement of sulfidic zinc ores produces large volumes of sulfur dioxide and cadmium vapor. Smelter slag and other residues contain significant quantities of metals. About 1.1 million tonnes of metallic zinc and 130 thousand tonnes of lead were mined and smelted in the Belgian towns of La Calamine and Plombières between 1806 and 1882. The dumps of the past mining operations leach zinc and cadmium, and the sediments of the Geul River contain non-trivial amounts of metals. About two thousand years ago, emissions of zinc from mining and smelting totaled 10 thousand tonnes a year. After increasing 10-fold from 1850, zinc emissions peaked at 3.4 million tonnes per year in the 1980s and declined to 2.7 million tonnes in the 1990s, although a 2005 study of the Arctic troposphere found that the concentrations there did not reflect the decline. Man-made and natural emissions occur at a ratio of 20 to 1. Zinc in rivers flowing through industrial and mining areas can be as high as 20 ppm. Effective sewage treatment greatly reduces this; treatment along the Rhine, for example, has decreased zinc levels to 50 ppb. Concentrations of zinc as low as 2 ppm adversely affects the amount of oxygen that fish can carry in their blood.
=== 2000-present === In 2000, the company opened a central laboratory in Singapore, building on clinical-development services formed in Singapore in 1996. In 2013, it expanded the capacity of the laboratory by 50%. In March 2001, the company sold Covance Pharmaceutical Packaging Services to Fisher Scientific for $137.5 million. In August 2005, it acquired GFI Clinical Services, an 80-bed clinical pharmacology business, from West Pharmaceutical Services for $5.7 million. In April 2006, the company acquired eight early phase clinical pharmacology sites from Radiant Research for $65 million. In June 2006, it acquired Signet Laboratories, a provider of monoclonal antibodies used in the research of cancer, infectious disease, and neurodegenerative disease, for $8.95 million. In 2007, the company opened a laboratory in Shanghai, China. In 2019, it opened a research and development center in Shanghai. In August 2008, the company acquired a campus in Greenfield, Indiana from Eli Lilly and Company and executed a 10-year service drug development service agreement with Lilly. In December 2008, the company acquired a minority equity stake in Caprion Proteomics, a provider of proteomics-based services to the pharmaceutical industry. The company was acquired by Chicago Growth Partners in July 2012. In 2009, the company acquired the Gene Expression Laboratory from Merck & Co. and entered into a five-year, $145 million contract to provide Merck with genomic analysis services.
Sources: en.wikipedia.org
Large sums from drug revenues were brought in from Miami and elsewhere to Panama for laundering, and Noriega received protection payments in these instances as well. American Steven Kalish also began a large scale business selling drugs, laundering money and selling hardware to the Panamanian military for considerable profits with Noriega's assistance. Dinges writes that at the time of the 1984 election, Kalish was preparing to ship a load of marijuana worth U.S. $1.4 million through Panama, for which Noriega had agreed to provide false Panamanian customs stamps; Noriega was to be paid $1 million for this exercise. Beginning in 1984, Noriega appeared to reduce the scale of his operations, and even ordered a raid against a cocaine factory in the interior of Panama, a raid which he then emphasized as evidence of his cooperation with the U.S. in their fight against drugs. He also ordered a crackdown on money laundering by Colombian cartel figures Jorge Ochoa and Gilberto Rodríguez Orejuela. Noriega's new image as an opponent of drug trafficking was symbolized by his being invited as a speaker in 1985 to Harvard University, for a conference on the role of the military in Central America's wars, a speech which received a lot of attention in Panama's pro-government press. In 1986, a convoluted operation involving the East German Stasi and the Danish ship Pia Vesta ultimately aimed to sell Soviet arms and military vehicles to South Africa's Armscor, with the Soviets using various intermediaries to distance themselves from the deal.
=== Side effects and contraindications === Research has shown a limited side effect profile for honokiol, and it appears to be well tolerated. However, its antithrombotic effects could cause hemorrhage especially in patients with conditions that would put them at a higher risk like hemophilia or Von Willebrand disease. Additionally, patients already taking anticoagulants should talk to their doctor before taking honokiol supplements. In a 2002 study, researchers induced cell death in fetal rat cortical neurons by directly applying 100μM in vitro.
The case Blizzard Entertainment v. Valve Corporation was settled out of court in May 2012; Valve retained the right to use Dota commercially, while Blizzard reserved the right for fans to use Dota non-commercially. Blizzard changed the names of its own projects to remove the Dota term, and renamed Blizzard All-Stars as Heroes of the Storm. Valve's Dota 2 was released in 2013. In 2014, mobile developers Lilith and uCool released its games Dota Legends and Heroes Charge, respectively. Both were influenced by Dota and the sequels. In 2017, Valve and Blizzard took joint action against these companies, citing copyright issues related to the Dota names. uCool argued that the Dota games were a collective work and could not be copyrighted by anyone in particular, but the presiding judge, Charles R. Breyer, felt that, due to the trio's actions as maintainers of the Dota mods, they had a rightful copyright claim to this. Separately, Lilith and uCool argued that Eul had, in a forum post from September 2004, assigned an open-source copyright license to Dota, which would make Valve and Blizzard's copyright claims void. The case was later heard by a jury.
Estrone levels surpass estradiol levels at around 2 hours post-dose and reach a maximum at about 4 hours. It has been speculated that the high delayed levels of estrone with sublingual estradiol may be due to the rich lymphatic drainage in the neck region, which may result in estradiol being taken up by the reticuloendothelial system and then metabolized into estrone. Sublingual administration of a single 0.25 mg tablet of micronized estradiol has been found to produce peak levels of 300 pg/mL estradiol and 60 pg/mL estrone within 1 hour. A higher dose of 1 mg estradiol was found to result in maximum levels of 450 pg/mL estradiol and 165 pg/mL estrone, which was followed by a rapid decline in estradiol levels to 85 pg/mL within 3 hours. Conversely, the decline in estrone levels was much slower and reached a level of 80 pg/mL after 18 hours. A single administration of 4 mg micronized estradiol (two 2-mg Estrace tablets) under the tongue, considered a very high dose of sublingual estradiol, has been found to result in maximal levels of estradiol of 1759 ± 704 pg/mL, with a range of 634 to 2840 pg/mL, after 1 hour in a mixed group of normotensive and hypertensive postmenopausal women. A replication of this study using the same dosage and protocols measured estradiol levels of 2227 ± 1180 pg/mL for the whole group of women but found that estradiol levels between the normotensive and hypertensive groups were significantly different at 1790 ± 869 pg/mL and 2664 ± 1490 pg/mL, respectively.
According to Human Rights Watch, as of 2009 Syria's poor human rights situation had "deteriorated further". Authorities arrested political and human rights activists, censored websites, detained bloggers, and imposed travel bans. Syria's multiple security agencies continue to detain people without arrest warrants. No political parties were licensed and emergency rule, imposed in 1963, remained in effect. Various torture techniques deployed in Syrian detention centres and prisons include routine beatings, rapes, sexual violence, "Bisat al-rih" (flying carpet), etc. Before the outbreak of Syrian revolution in 2011, Ba'athist Syria's human rights situation was regarded as among the worst in the world. Ba'athist military apparatus arbitrarily arrested numerous civilians, tortured dissidents and violently persecuted Syrian Kurds. The Syrian police continued to arrest journalists, target human rights activists, censor websites, ban media outlets, detain bloggers, and impose travel bans. Arbitrary detentions, torture, and forced disappearances were widespread. Kurdish dissidents and political activists were regularly arrested and imprisoned. Expressions of Kurdish identity were banned, with Kurds being systematically discriminated and treated as "second-class citizens" in Ba'athist Syria. The scale of the brutal violence and state terrorism unleashed by the Assad regime and his foreign backers across the country after the eruption of the 2011 Syrian revolution was unprecedented, far outstripping the actions of other Arab autocrats who repressed the Arab Spring.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.